EB-DTNB-NK Clinical Trials

1 actively recruiting trial

Also known as: Dual-target GD2/B7-H3 CAR-NK

Pipeline

Phase 1/2: 1

Top Sponsors

Beijing Biotech1

Indications

Ganglioneuroblastoma1
High-risk Neuroblastoma1
Refractory Neuroblastoma1
Relapsed Neuroblastoma1
Cancer1

Other1 trial

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.